Seoane IV, Martínez C, García-vicuña R, et al. Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis.
Sci Rep. 2018;8(1):2035.
Comparison of Neuropeptide Innervation in Allergic and Nonallergic Rhinitis.
Eraydin U, Gunel C, Kozaci LD, Erkus M, Basak HS. Journal of Otology & Rhinology. 2014;3:4.
Martínez C, Ortiz AM, Juarranz Y, et al. Serum levels of vasoactive intestinal peptide as a prognostic marker in early arthritis.
PLoS ONE. 2014;9(1):e85248.
El-shazly AE, Begon DY, Kustermans G, et al. Novel association between vasoactive intestinal peptide and CRTH2 receptor in recruiting eosinophils: a possible biochemical mechanism for allergic eosinophilic inflammation of the airways.
J Biol Chem. 2013;288(2):1374-84.
Levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients.
Buljevic S, Detel D, Pucar LB, et al. Rheumatol Int. 2013;33(11):2867-74.
Mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis.
Cobo M, Anderson P, Benabdellah K, et al. Cell Transplant. 2013;22(5):839-54.
Relation between stressful life events, neuropeptides and cytokines: results from the LISA birth cohort study.
Herberth G, Weber A, Röder S, et al. Pediatr Allergy Immunol. 2008;19(8):722-9.
Functional adaptation to loading of a single bone is neuronally regulated and involves multiple bones.
Sample SJ, Behan M, Smith L, et al. J Bone Miner Res. 2008;23(9):1372-81.
In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis.
Delgado M, Toscano MG, Benabdellah K, et al. Arthritis Rheum. 2008;58(4):1026-37.
Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts.
Juarranz Y, Gutiérrez-cañas I, Santiago B, Carrión M, Pablos JL, Gomariz RP. Arthritis Rheum. 2008;58(4):1086-95.
Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.
Valdehita A, Carmena MJ, Collado B, Prieto JC, Bajo AM. Regul Pept. 2007;144(1-3):101-8.
Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.
Fernández-martínez AB, Collado B, Bajo AM, Sánchez-chapado M, Prieto JC, Carmena MJ. Mol Cell Endocrinol. 2007;270(1-2):8-16.
Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis.
Sun W, Hong J, Zang YC, Liu X, Zhang JZ. Int Immunol. 2006;18(12):1691-700.
Association of neuropeptides with Th1/Th2 balance and allergic sensitization in children.
Herberth G, Daegelmann C, Weber A, et al. Clin Exp Allergy. 2006;36(11):1408-16.
Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells.
Collado B, Sánchez-chapado M, Prieto JC, Carmena MJ. Mol Cell Endocrinol. 2006;249(1-2):116-22.
Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis.
Grimsholm O, Rantapää-dahlqvist S, Forsgren S. Arthritis Res Ther. 2005;7(3):R416-26.
